RecruitingPhase 3NCT07665437

An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS

A Double-blind, Double-dummy, Parallel Group, Multicenter Phase 3 Extension Study Evaluating the Long-term Safety and Efficacy of 2 Doses of Remibrutinib in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

Sponsor

Novartis Pharmaceuticals

Enrollment

710 participants

Start Date

Jul 10, 2026

Study Type

INTERVENTIONAL

Conditions

Hidradenitis Suppurativa

Summary

The purpose of this study is to evaluate the long-term safety, tolerability and efficacy of remibrutinib (LOU064) in adult participants with moderate to severe hidradenitis suppurativa (HS) who have completed either of the preceding Phase 3 studies, CLOU064J12301 or CLOU064J12302.

Eligibility

Min Age: 18 YearsMax Age: 100 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Remibrutinib for people with hidradenitis suppurativa. The study is currently recruiting participants at 4 locations. People eligible for this study include aged 18 Years to 100 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.